With the U.S. authorization for urologic procedures, “there is now choice” for hospitals that want to expand their robotic ...

The long-awaited FDA clearance sets up a showdown in the surgical robotics market between Medtronic and Intuitive Surgical.

Medtronic (NYSE: MDT) announced today that the FDA cleared its Hugo robotic-assisted surgery system for use in urologic surgical procedures.

The global surgical robotics market is forecast to grow at a compound annual growth rate (CAGR) of 15% between 2025 and 2030.

Hugo is heading to the U.S., with Medtronic finally securing a stateside clearance for its robotic surgery platform. | The ...

With FDA clearance, the Hugo RAS system is indicated for use in minimally invasive urologic surgical procedures including prostatectomy, nephrectomy, and cystectomy — common procedures that account ...

Medtronic's Hugo surgical robot gained FDA clearance for urologic procedures, opening U.S. market entry and setting the stage ...

FDA clears Medtronic robot for urologic surgeries, enabling use in prostatectomy, nephrectomy and cystectomy across select U.S. hospitals.

Two peer-reviewed studies published in 2024 have established that patients with large, complex hiatal hernias achieve significantly better surgical outcomes when treated by experienced specialists ...

Nashik: Prof Dr Raj Nagarkar, Managing Director & Chief of Surgical Oncology and Robotic Services at HCG Manavata Cancer ...

Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), a commercial-stage medical device company that develops and markets AI-powered, MRI-guided, incision-free therapies for ...